Sichuan Center for Disease Control and Prevention
14
3
4
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
79%
11 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Role: collaborator
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Role: collaborator
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
Role: collaborator
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
Role: collaborator
Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population
Role: collaborator
Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP
Role: collaborator
Phase I Clinical Protocol of BCG-PPD in Healthy People
Role: collaborator
A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly
Role: collaborator
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Role: collaborator
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
Role: collaborator
The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine
Role: lead
Post-License Safety Evaluation of Influenza Virus Vaccine
Role: lead
Injecting Drug Use Community Intervention Trial
Role: collaborator
(Men Who Have Sex With Men) MSM Community Intervention Trial
Role: collaborator
All 14 trials loaded